Quality-of-life (QOL) assessment in patients (pts) with metastatic melanoma receiving vemurafenib (V) and cobimetinib (C).
Brigitte Dréno(Inserm), Antoni Ribas(University of California, Los Angeles), Gabriella Liszkay(National Institute of Oncology), Lev Demidov(Heidelberg University), Luis de la Cruz‐Merino, Michele Maio(University of Siena), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Grant A. McArthur(The University of Melbourne), Ilsung Chang, Stephen P. Hack, Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Daniil Stroyakovskiy(Shikoku Cancer Center), James Larkin(Trinity College Dublin), L. Thomas, Victoria Atkinson(Greenslopes Private Hospital), Claus Garbe(University Children's Hospital Tübingen), Karen Bartley(Genesys (United States)), Mario Mandalà(University of Perugia)
Cited by 7
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2019|3.7k